Dyne Therapeutics, Inc. — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023. Unaudited results. Dyne is a clinical-stage biotechnology company developing muscle-disease therapeutics using its FORCE platform; it has no approved products and has generated no revenue.
Financial performance and position
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $55.3 million | $34.7 million | $151.9 million | $109.6 million |
| General and administrative expense | $7.0 million | $7.6 million | $22.6 million | $21.2 million |
| Operating expenses | $62.3 million | $42.3 million | $174.5 million | $130.8 million |
| Net loss | $60.2 million | $41.4 million | $169.3 million | $129.3 million |
| Basic and diluted net loss per share | $0.99 | $0.80 | $2.86 | $2.50 |
| Net cash used in operating activities | Not stated for quarter | Not stated for quarter | $153.2 million | $124.5 million |
Balance sheet at September 30, 2023: Cash and cash equivalents were $130.3 million and marketable securities were $27.5 million, or $157.8 million combined; restricted cash was an additional $2.3 million. Current assets were $168.2 million and current liabilities $29.7 million. Total liabilities were $53.2 million, including $28.2 million of lease liabilities; the filing reports no borrowings or other debt. Stockholders’ equity was $152.0 million and accumulated deficit was $565.9 million.
Margins: Not meaningful because Dyne reported no revenue. Interest income was $2.2 million in Q3 and $5.9 million for the first nine months of 2023, versus $0.9 million and $1.6 million, respectively, in 2022.
Changes versus prior comparable periods
- Q3 operating expenses increased $20.0 million year over year, primarily from a $20.6 million increase in R&D. R&D growth reflected clinical-trial and manufacturing activity for DYNE-101 and DYNE-251, higher preclinical platform activity, and increased R&D headcount.
- Q3 net loss widened by $18.8 million. For the first nine months, operating expenses rose $43.7 million and net loss widened by $40.0 million year over year.
- Cash, cash equivalents and marketable securities declined from $256.0 million at December 31, 2022 to $157.8 million at September 30, 2023. The company raised $52.4 million net through its at-the-market equity program during the first nine months, issuing 4.5 million shares at a weighted-average price of $12.01.
- Research and development accounted for the increase in spending: nine-month DYNE-101 expense rose to $48.6 million from $23.5 million; DYNE-251 expense rose to $45.6 million from $41.0 million. G&A increased modestly to $22.6 million from $21.2 million.
Outlook, programs and risks
- Management said existing cash, cash equivalents and marketable securities should fund operating expenses and capital expenditures through 2024 and, in the MD&A, said it expects to reach proof-of-concept readouts for DYNE-101 and DYNE-251. A separate financial-statement note states resources are expected to be sufficient for at least 12 months from issuance. Both estimates depend on assumptions and could change; additional financing will be needed to sustain development.
- DYNE-101 (DM1): Phase 1/2 ACHIEVE had enrolled 40 participants in the first two multiple-ascending-dose cohorts; cohort 3, up to 6.8 mg/kg, was enrolling. Management anticipated initial safety, tolerability, splicing and myotonia-function data in early January 2024. FDA and EMA orphan-drug designations were reported.
- DYNE-251 (DMD, exon 51 skipping): Phase 1/2 DELIVER had enrolled 32 participants across five cohorts; cohort 6, up to 20 mg/kg, was enrolling. Management anticipated initial safety, tolerability and dystrophin-expression data in early January 2024. The FDA had granted orphan-drug and rare-pediatric-disease designations; the filing also reports FDA Fast Track designation. The earlier FDA clinical hold was cleared in July 2022.
- DYNE-301 for FSHD had been deferred as the company prioritized DYNE-101 and DYNE-251; management planned to provide an FSHD program update by year-end 2023.
- Management reported no treatment-emergent anemia or discontinuations to date in the described DYNE-101 and DYNE-251 trial cohorts. These are interim observations, not evidence of efficacy or a guarantee of future safety.
- Key risks include clinical failure or delay, uncertainty around the FORCE platform, dependence on third-party and single-source manufacturers and CROs, patient enrollment challenges, competition, intellectual-property and licensing risks, and the need for additional capital. Future equity financing could dilute shareholders; collaboration or licensing could require surrendering valuable rights.
- No legal proceedings were reported. The company disclosed no material changes in internal control over financial reporting and stated disclosure controls were effective at a reasonable-assurance level. No unregistered securities sales or other information were reported under the relevant items.
Most important facts for investors to verify
- Whether the anticipated DYNE-101 and DYNE-251 readouts occurred on schedule and what the full safety, pharmacodynamic and functional data show.
- Whether trial enrollment, dose escalation and regulatory plans remain on track, including criteria for further escalation.
- Whether the stated cash runway through 2024 remains achievable as clinical, manufacturing and platform spending increases; reconcile management’s runway statements with actual subsequent cash burn and financing.
- Remaining capacity under the $150 million ATM program, subsequent share issuance and resulting dilution.
- Whether DYNE-301’s planned update changed its development status or resource priority.